Elevated levels of SRSF1 upregulated PRKCH and PLCH1 mechanistically, leading to impaired imatinib sensitivity in patients with CML [92] (Table 1). This evidence concerns the gene SRSF1 and chronic myelogenous leukemia, BCR-ABL1 positive.